



## Porcine Virus and Vaccines

Guest Editor:

### **Dr. Huixing Lin**

College of Veterinary Medicine,  
Nanjing Agricultural University,  
Nanjing, China

Deadline for manuscript  
submissions:

**closed (25 October 2024)**

### **Message from the Guest Editor**

Viruses may affect different systems of porcine, e.g., the gastrointestinal system, respiratory system, reproductive system, central nervous system, and heart, resulting in various porcine diseases. The virus causes serious losses to swine production every year, such as the African swine fever virus (ASFV), porcine epidemic diarrhea virus (PEDV), and porcine respiratory and reproductive dysfunction syndrome virus (PRRSV). It is an important measure for disease prevention to study the pathogenic mechanism of viruses and develop targeted vaccines. New immune adjuvants and optimization of administration routes may affect the immune effect of porcine vaccines. This Special Issue will gather the latest advances in porcine viruses and their vaccines.

Potential topics for this Special Issue include but are not limited to the following:

- Discovery and virulence identification of a new porcine virus;
- Immunosuppressive or pathogenic mechanism of a porcine virus;
- Development of a new porcine virus vaccine;
- Immunological assessment of a porcine vaccine;
- Immune adjuvants for a porcine vaccine;
- Optimization of administration route and/or formula in a porcine vaccine.





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

**Journal Rank:** JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)  
[X@Vaccines\\_MDPI](https://twitter.com/Vaccines_MDPI)